Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Newly Launched Replay Has Big Plans For Writing and Delivering ‘Big DNA’

Viral Vector Has 30 Times Capacity Of AAV

Executive Summary

With a hub-and-spoke model, Replay has ambitious plans to solve multiple problems in genetic medicine and to disrupt the current AAV gene therapy model.

You may also be interested in...



Gilead And Arcus’ Latest Update Keeps TIGIT Hopes Afloat

Gilead and Arcus believe their ‘Fc silent’ TIGIT inhibitor candidate could be best in class, but analysts think only outstanding results in lung cancer will sway investor sentiment.

Questions About Gantenerumab Failure Remain, But Roche Is Not Yet Finished With Alzheimer’s

Roche’s global head of neurodegeneration, Rachelle Doody, talks to Scrip about the failure of gantenerumab and its next-generation ‘brain shuttle’ technology for Alzheimer’s disease.

Speculation Grows On Potential Big Pharma Buyout Of Mirati

Several big pharma companies may be interested in buying Mirati, but could baulk at paying up to $12bn for its as-yet-unproven oncology portfolio.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146765

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel